MedTrace Logo

Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease

NCT00970970 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2024-05-06

No results posted yet for this study

Summary

Von Hippel Lindau disease (VHLD) is an inherited syndrome characterized by vascular malformations, kidney cancer, adrenal gland and pancreas tumors. The VHL protein is not functional in the different disease associated lesions which results in production of high amounts of vascular endothelial growth factor (VEGF). Currently there are no clinical, radiographic or molecular markers that can predict the natural history of a given lesion. With 89Zr-bevacizumab positron emission tomography (PET) scanning, VEGF can be visualized and quantified.

The investigators hypothesize that 89Zr-bevacizumab PET imaging is a useful tool to predict the behaviour of disease associated lesions in patients with VHLD.

Adult patients with VHLD who have had routine magnetic resonance imaging (MRI) scans of central nervous system (CNS) and abdomen will undergo a 89Zr-bevacizumab PET scan. MRI will be repeated within 12 months.

Conditions

  • Von Hippel-Lindau Disease
  • Hemangioblastoma
  • Renal Cell Carcinoma
  • Pheochromocytoma
  • Pancreatic Neuroendocrine Tumor

Interventions

OTHER

89Zr bevacizumab PET scan

Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.

Sponsors & Collaborators

  • VHL Alliance

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Sjoukje Oosting, MD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970970 on ClinicalTrials.gov